For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Astrazeneca plc ADR (NASDAQ: AZN) closed at $79.54 in the last session, up 0.53% from day before closing price of $79.12. In other words, the price has increased by $0.53 from its previous closing price. On the day, 3.68 million shares were traded. AZN stock price reached its highest trading level at $79.8 during the session, while it also had its lowest trading level at $79.22.
Ratios:
We take a closer look at AZN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.46. For the most recent quarter (mrq), Quick Ratio is recorded 0.67 and its Current Ratio is at 0.86. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Exane BNP Paribas on April 15, 2025, initiated with a Outperform rating and assigned the stock a target price of $75.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 246612180992 and an Enterprise Value of 148558004224. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.84, and their Forward P/E ratio for the next fiscal year is 15.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.36 while its Price-to-Book (P/B) ratio in mrq is 5.52. Its current Enterprise Value per Revenue stands at 2.629 whereas that against EBITDA is 7.767.
Stock Price History:
The Beta on a monthly basis for AZN is 0.38, which has changed by -0.070360005 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, AZN has reached a high of $87.68, while it has fallen to a 52-week low of $61.24. The 50-Day Moving Average of the stock is 9.44%, while the 200-Day Moving Average is calculated to be 12.83%.
Shares Statistics:
According to the various share statistics, AZN traded on average about 4.56M shares per day over the past 3-months and 3888160 shares per day over the past 10 days. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.01% of the company’s shares, while institutions hold 16.27% stake in the company. Shares short for AZN as of 1753920000 were 5326651 with a Short Ratio of 1.17, compared to 1751241600 on 6811704. Therefore, it implies a Short% of Shares Outstanding of 5326651 and a Short% of Float of 0.16999999999999998.
Dividends & Splits
The forward annual dividend rate for AZN is 1.56, which was 3.13 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.03956016The stock’s 5-year Average Dividend Yield is 2.26. The current Payout Ratio is 66.95% for AZN, which recently paid a dividend on 2025-08-08 with an ex-dividend date of 2025-08-08. Stock splits for the company last occurred on 2015-07-27 when the company split stock in a 2:1 ratio.
Earnings Estimates
The stock of Astrazeneca plc ADR (AZN) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $1.09, with high estimates of $1.12 and low estimates of $1.03.
Analysts are recommending an EPS of between $4.59 and $4.51 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $5.11, with 5.0 analysts recommending between $5.24 and $4.91.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $14.76B. It ranges from a high estimate of $14.99B to a low estimate of $14.47B. As of the current estimate, Astrazeneca plc ADR’s year-ago sales were $13.56BFor the next quarter, 9 analysts are estimating revenue of $15.38B. There is a high estimate of $15.72B for the next quarter, whereas the lowest estimate is $14.96B.
A total of 21 analysts have provided revenue estimates for AZN’s current fiscal year. The highest revenue estimate was $59.09B, while the lowest revenue estimate was $56.72B, resulting in an average revenue estimate of $58.31B. In the same quarter a year ago, actual revenue was $54.07BBased on 20 analysts’ estimates, the company’s revenue will be $61.94B in the next fiscal year. The high estimate is $64.96B and the low estimate is $57.59B.
